EP1379132A4 - HUMAN SECRETED PROTEINS - Google Patents

HUMAN SECRETED PROTEINS

Info

Publication number
EP1379132A4
EP1379132A4 EP02760994A EP02760994A EP1379132A4 EP 1379132 A4 EP1379132 A4 EP 1379132A4 EP 02760994 A EP02760994 A EP 02760994A EP 02760994 A EP02760994 A EP 02760994A EP 1379132 A4 EP1379132 A4 EP 1379132A4
Authority
EP
European Patent Office
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02760994A
Other languages
German (de)
French (fr)
Other versions
EP1379132A2 (en
Inventor
Craig A Rosen
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1379132A2 publication Critical patent/EP1379132A2/en
Publication of EP1379132A4 publication Critical patent/EP1379132A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP02760994A 2001-03-21 2002-03-19 HUMAN SECRETED PROTEINS Withdrawn EP1379132A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US277340P 2001-03-21
US30617101P 2001-07-19 2001-07-19
US306171P 2001-07-19
US33128701P 2001-11-13 2001-11-13
US331287P 2001-11-13
PCT/US2002/008278 WO2002102994A2 (en) 2001-03-21 2002-03-19 Human secreted proteins

Publications (2)

Publication Number Publication Date
EP1379132A2 EP1379132A2 (en) 2004-01-14
EP1379132A4 true EP1379132A4 (en) 2009-07-01

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
EP02780789A Withdrawn EP1423134A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02749512A Withdrawn EP1381622A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02799146A Withdrawn EP1390390A4 (en) 2001-03-21 2002-03-19 HUMAN SECRETED PROTEINS
EP02759068A Withdrawn EP1404702A4 (en) 2001-03-21 2002-03-19 HUMAN SECRETED PROTEINS
EP02782476A Withdrawn EP1414845A4 (en) 2001-03-21 2002-03-19 HUMAN SECRETED PROTEINS
EP02723499A Withdrawn EP1379264A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02760994A Withdrawn EP1379132A4 (en) 2001-03-21 2002-03-19 HUMAN SECRETED PROTEINS

Family Applications Before (6)

Application Number Title Priority Date Filing Date
EP02780789A Withdrawn EP1423134A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02749512A Withdrawn EP1381622A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
EP02799146A Withdrawn EP1390390A4 (en) 2001-03-21 2002-03-19 HUMAN SECRETED PROTEINS
EP02759068A Withdrawn EP1404702A4 (en) 2001-03-21 2002-03-19 HUMAN SECRETED PROTEINS
EP02782476A Withdrawn EP1414845A4 (en) 2001-03-21 2002-03-19 HUMAN SECRETED PROTEINS
EP02723499A Withdrawn EP1379264A4 (en) 2001-03-21 2002-03-19 Human secreted proteins

Country Status (4)

Country Link
EP (7) EP1423134A2 (en)
AU (6) AU2002354719A1 (en)
CA (7) CA2441417A1 (en)
WO (7) WO2003038063A2 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
JP2002513295A (en) 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 123 human secreted proteins
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
DE69941187D1 (en) 1998-06-01 2009-09-10 Agensys Inc SERPENTINTRANSMEMBRANANTIGENE EXPRESSED IN HUMAN CANCER AND ITS USES
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
EA004590B1 (en) 1999-01-15 2004-06-24 Байоджен, Инк. Method for blocking the development or treating or reducing the severity or effects of "transplant against patients" disease
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7335731B2 (en) 2000-07-25 2008-02-26 Genentech, Inc. PRO4332 polypeptides
WO2002048370A2 (en) 2000-10-31 2002-06-20 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
EP1573024A4 (en) * 2001-04-10 2007-08-29 Agensys Inc NUCLEIC ACIDS AND CORRESPONDING PROTEINS USEFUL FOR THE DETECTION AND TREATMENT OF VARIOUS CANCERS
US20030125521A1 (en) 2001-06-20 2003-07-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1439235A4 (en) 2001-10-12 2006-01-18 Astellas Pharma Inc CELL DEATH INHIBITOR SCREENING METHOD
AU2003224950B2 (en) 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7645602B2 (en) 2003-09-23 2010-01-12 The University Of North Carolina At Chapel Hill Methods and compositions for producing vitamin K dependent proteins
ATE455174T1 (en) 2003-09-23 2010-01-15 Univ North Carolina CELLS THAT COEXPRESS VITAMIN K REDUCTASE AND VITAMIN K DEPENDENT PROTEIN AND THEIR APPLICATION TO IMPROVE THE PRODUCTIVITY OF THIS VITAMIN K DEPENDENT PROTEIN
EP2272951B1 (en) * 2003-10-14 2014-07-23 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
EP1714154A2 (en) * 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
BRPI0418766B8 (en) 2004-04-22 2021-05-25 Agensys Inc antibody or fragment thereof, vector, pharmaceutical composition, assay and method for detecting the presence of step-1 protein, as well as a method for delivering a cytotoxic agent or a diagnostic agent
PL1794174T3 (en) * 2004-09-01 2012-11-30 Dynavax Tech Corp Methods and compositions for inhibition of innate immune responses and autoimmunity
EP1799850A4 (en) * 2004-09-07 2009-02-11 Telethon Inst For Child Health METHOD OF DIAGNOSING AND / OR PREDICTING DEVELOPMENT OF ALLERGIC DISEASE
US20100003241A1 (en) * 2004-09-07 2010-01-07 Patrick Holt Agents for treatment or prevention of an allergic disorder
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
KR101310532B1 (en) 2005-02-28 2013-09-23 박스터 헬쓰케어 에스에이 Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2007025347A1 (en) * 2005-09-01 2007-03-08 Howard Florey Institute Of Experimental Physiology And Medicine Prophylactic and therapeutic agents and uses therefor
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
PT2845866T (en) 2006-10-27 2017-08-09 Genentech Inc ANTIBODIES AND IMMUNOCONUELS AND UTILIZATIONS THEREOF
CA2667894A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2142217B1 (en) * 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2209896B1 (en) 2007-10-26 2017-03-01 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
WO2009070350A1 (en) * 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
WO2010068526A1 (en) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
AU2010313324A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX213 and AX132 PCSK9 antagonists and variants
CA2777698A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
CN103153346A (en) 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 Methods of treatment using tlr7 and/or tlr9 inhibitors
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Ways to treat or prevent cholesterol disorders
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
EA039663B1 (en) 2012-05-03 2022-02-24 Амген Инк. Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
KR102379464B1 (en) 2016-06-20 2022-03-29 키맵 리미티드 anti-PD-L1 antibody
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR102569848B1 (en) 2016-12-23 2023-08-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Gene editing of PCSK9
PE20200010A1 (en) 2017-04-03 2020-01-06 Hoffmann La Roche ANTIBODIES THAT JOIN STEAP-1
CN122061123A (en) * 2017-06-22 2026-05-19 宝洁公司 Membranes including water-soluble layers and vapor-deposited inorganic coatings
EP3641951B1 (en) 2017-06-22 2023-09-20 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited organic coating
US12115230B2 (en) 2020-04-09 2024-10-15 Verve Therapeutics, Inc. Base editing of ANGPTL3 and methods of using same for treatment of disease
EP4132951A4 (en) 2020-04-09 2025-06-11 Verve Therapeutics, Inc. Chemically modified guide rnas for genome editing with cas12b
MX2024001877A (en) 2021-08-10 2024-02-28 Kymab Ltd Treatment of atopic dermatitis.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (en) * 1996-02-02 1999-12-15 나까니시 히로유끼 A pharmaceutical preparation containing a human growth hormone
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins

Also Published As

Publication number Publication date
EP1390390A2 (en) 2004-02-25
WO2002102993A3 (en) 2004-03-25
CA2441397A1 (en) 2002-10-03
WO2003004622A2 (en) 2003-01-16
WO2003004622A3 (en) 2004-02-19
WO2002102993A2 (en) 2002-12-27
AU2002326293A1 (en) 2003-01-02
WO2002102994A3 (en) 2003-07-24
EP1404702A2 (en) 2004-04-07
EP1404702A4 (en) 2009-07-08
CA2441840A1 (en) 2002-11-28
EP1390390A4 (en) 2009-07-08
EP1423134A2 (en) 2004-06-02
CA2441417A1 (en) 2002-11-14
CA2441702A1 (en) 2002-12-27
WO2002095010A3 (en) 2004-02-12
WO2002076488A1 (en) 2002-10-03
CA2441755A1 (en) 2003-05-08
EP1379264A4 (en) 2009-07-08
AU2002320013A1 (en) 2002-11-18
WO2003038063A2 (en) 2003-05-08
AU2002354719A1 (en) 2003-01-21
WO2003038063A3 (en) 2003-12-11
WO2002090526A2 (en) 2002-11-14
AU2002332391A1 (en) 2003-01-02
EP1414845A4 (en) 2009-07-08
AU2002363296A1 (en) 2003-05-12
EP1379132A2 (en) 2004-01-14
EP1414845A2 (en) 2004-05-06
WO2002095010A2 (en) 2002-11-28
AU2002324424A1 (en) 2002-12-03
CA2441416A1 (en) 2003-01-16
WO2002102994A2 (en) 2002-12-27
WO2002090526A3 (en) 2003-10-30
CA2441832A1 (en) 2002-12-27
EP1381622A2 (en) 2004-01-21
EP1379264A1 (en) 2004-01-14

Similar Documents

Publication Publication Date Title
EP1404702A4 (en) HUMAN SECRETED PROTEINS
EP1506398A4 (en) HUMAN SECRETED PROTEINS
EP1181390A4 (en) 27 HUMAN SECRETED PROTEINS
EP1391209A4 (en) PROTEIN FORMULATIONS
EP1165827A4 (en) 45 HUMAN SECRETED PROTEINS
EP1175439A4 (en) 49 HUMAN SECRETED PROTEINS
EP1368468A4 (en) 83 HUMAN SECRETED PROTEINS
EP1159284A4 (en) 33 HUMAN SECRETED PROTEINS
EP1189917A4 (en) 48 HUMAN SECRETED PROTEINS
EP1185543A4 (en) 50 HUMAN SECRETED PROTEINS
EP1173477A4 (en) 49 HUMAN SECRETED PROTEINS
EP1171460A4 (en) 48 HUMAN SECRETED PROTEINS
EP1165828A4 (en) 50 HUMAN SECRETED PROTEINS
EP1317471A4 (en) 21 HUMAN SECRETED PROTEINS
EP1404807A4 (en) 20 HUMAN SECRETED PROTEINS
EP1185285A4 (en) 49 HUMAN SECRETED PROTEINS
EP1322657A4 (en) HUMAN SECRETED PROTEINS 22
EP1171626A4 (en) FIFTY HUMAN SECRETED PROTEINS
EP1322659A4 (en) 21 HUMAN SECRETED PROTEINS
EP1165591A4 (en) 47 HUMAN SECRETED PROTEINS
EP1165123A4 (en) 48 HUMAN SECRETED PROTEINS
EP1181303A4 (en) 50 HUMAN SECRETED PROTEINS
EP1317467A4 (en) 7 HUMAN SECRETED PROTEINS
EP1187908A4 (en) 42 HUMAN SECRETED PROTEINS
EP1165590A4 (en) 49 HUMAN SECRETED PROTEINS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031021

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20090603

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/02 20060101ALI20090527BHEP

Ipc: C07K 1/00 20060101AFI20090527BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090903